Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D09ZIO
|
||||
| Former ID |
DAP000285
|
||||
| Drug Name |
Eptifibatide
|
||||
| Synonyms |
Integrelin; Integrilin; Intrifiban; HS-2011; Integrilin (TN); SB-1; Sch-60936; N(6)-amidino-N(2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; N(sup 6)-Amidino-N(sup 2)-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide; S(1),S(6)-cyclo[N(6)-carbamimidoyl-N(2)-(3-sulfanylpropanoyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide]; L-Cysteinamide, N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-prolyl-, cyclic (1-6)-disulfide; L-Cysteinamide,N6-(aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophy-L-propyl-,cyclic (1-6)-disulfide; [(3R,11S,17S,20S,25aS)-11-(4-carbamimidamidobutyl)-3-carbamoyl-20-(1H-indol-3-ylmethyl)-1,9,12,15,18,21-hexaoxodocosahydro-7H-pyrrolo[2,1-g][1,2,5,8,11,14,17,20]dithiahexaazacyclotricosin-17-yl]acetic acid; 2-[(3S,6S,12S,20R,23S)-20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid; 2-[20-carbamoyl-12-[4-(diaminomethylideneamino)butyl]-3-(1H-indol-3-ylmethyl)-2,5,8,11,14,22-hexaoxo-17,18-dithia-1,4,7,10,13,21-hexazabicyclo[21.3.0]hexacosan-6-yl]acetic acid
|
||||
| Drug Type |
Small molecular drug
|
||||
| Therapeutic Class |
Anticoagulants
|
||||
| Company |
Millennium Pharmaceuticals
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C35H49N11O9S2
|
||||
| InChI |
InChI=1S/C35H49N11O9S2/c36-30(51)25-18-57-56-13-10-27(47)42-22(8-3-4-11-39-35(37)38)31(52)41-17-28(48)43-23(15-29(49)50)32(53)44-24(14-19-16-40-21-7-2-1-6-20(19)21)34(55)46-12-5-9-26(46)33(54)45-25/h1-2,6-7,16,22-26,40H,3-5,8-15,17-18H2,(H2,36,51)(H,41,52)(H,42,47)(H,43,48)(H,44,53)(H,45,54)(H,49,50)(H4,37,38,39)/t22-,23-,24-,25-,26-/m0/s1
|
||||
| InChIKey |
CZKPOZZJODAYPZ-LROMGURASA-N
|
||||
| CAS Number |
CAS 188627-80-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
11528772, 12014752, 14747249, 14889413, 16531762, 37101828, 50112758, 57404888, 75281485, 85484373, 93815080, 103342240, 103990302, 104639978, 123120902, 135993536, 137018745, 141688477, 144206056, 152034624, 152344080, 162188582, 162224725, 165698503, 170465043, 175266937, 178103198, 179150113, 187072137, 196105788, 210279811, 210282134, 226406075, 249691274, 252158304, 252215360, 252669917
|
||||
| SuperDrug ATC ID |
B01AC16
|
||||
| SuperDrug CAS ID |
cas=188627807
|
||||
| Target and Pathway | |||||
| Target(s) | Glycoprotein IIb/IIIa receptor | Target Info | Modulator | [530803] | |
| Reactome | Platelet degranulation | ||||
| Elastic fibre formation | |||||
| PECAM1 interactions | |||||
| Molecules associated with elastic fibres | |||||
| Integrin cell surface interactions | |||||
| Syndecan interactions | |||||
| ECM proteoglycans | |||||
| Integrin alphaIIb beta3 signaling | |||||
| GRB2:SOS provides linkage to MAPK signaling for Integrins | |||||
| p130Cas linkage to MAPK signaling for integrins | |||||
| VEGFA-VEGFR2 Pathway | |||||
| MAP2K and MAPK activation | |||||
| References | |||||
| Ref 536361 | Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20. | ||||
| Ref 541705 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6585). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.